ArticleFrontiers in endocrinology2025
Association between RC/HDL-C and hyperuricemia in adults: evidence from NHANES 2005-2018.
Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Nonlinear associations of remnant cholesterol/high-density lipoprotein cholesterol ratio with the risk of metabolic-associated fatty liver disease: a cross-sectional study.BMC gastroenterology · 2026Article
- Nonlinear association of residual cholesterol to high-density lipoprotein cholesterol ratio with diabetes mellitus: a retrospective cohort study.Scientific reports · 2026Article
- Correlation of neutrophil- and high-density lipoprotein cholesterol-related inflammatory markers with sarcopenia: Insights from a cross-sectional study.The Journal of international medical research · 2026Article
- Remnant cholesterol: an independent, dose-dependent risk factor for hyperuricemia in a normolipidemic chinese population.Frontiers in endocrinology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The incidence of hyperuricemia is growing in the world, with a significant influence on the survival and healthy condition of the patient. The connection between serum residual cholesterol (RC) to high-density lipoprotein cholesterol (HDL-C) ratio and hyperuricemia is uncertain. Consequently, we tried to elucidate the connection between the hyperuricemia and RC/HDL-C ratio. Methods: Based on the National Health and Nutrition Examination Survey (NHANES) database, data from 2005 to 2018 were utilized in this cross-sectional research. RC/HDL-C index was calculated by (TC - HDL-C - LDL-C)/HDL-C. Participants were diagnosed with hyperuricemia when the serum uric acid concentration reached 6 mg/dL in women and 7 mg/dL in men. Our researcher utilized smoothed curve fitting and multivariate logistic regression analysis to examine between RC/HDL-C and hyperuricemia among adults. The consistency of these results was examined in various population subgroups. Results: 2376 individuals (19.1%) were stratified into the hyperuricemia group. We observed statistically significant differences (P values < 0.05) in the hyperuricemia population for remaining variables, except for economic level and alcohol drinking. After correcting for potential confounders, our researchers discovered the strong positive connection between the RC/HDL-C and the possibility of incurring hyperuricemia. The incidence of RC/HDL-C elevated by 98% with each additional unit of the RC/HDL-C. Subgroup analyses showed correlations for the majority of subgroups remained stable. However, gender and several diseases may modify this association. Conclusions: Higher RC/HDL-C is correlated with higher prevalence rate of developing hyperuricemia. However, further research is still required to confirm the causal association.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.